Cardiology

Following is a digest of pharmacogenomics journal articles pertaining to cardiology. The SNP•its editorial team selects articles for inclusion based on clinical relevance and scientific validity. Journal articles that are most readily applicable and relevant to practicing clinicians are selected for a SNP•its Study Summary, which discusses findings and clinical implications of a pharmacogenomics study in the context of the larger evidence base.

Article Citation & LinkTypeMonthSNP•its Study Summary
Nakkam N et al. The impact of genetic polymorphisms of drug metabolizing enzymes on the pharmacodynamics of clopidogrel under steady state conditions. Drug Metab Pharmacokinet. 2015;30:295-304.PK/PDPK/PD
Alzubiedi S et al. Pharmacogenetic-guided warfarin dosing algorithm in African-Americans. J Cardiovasc Pharmacol. 2016;67:86-92.Review2016-01
Leusink M et al. Seventeen years of statin pharmacogenetics: a systematic review. Pharmacogenomics. 2016;17:163-80.Systematic Review2016-01
Sridharan K et al. Association of genetic polymorphisms of CYP2C9 and VKORC1 with bleeding following warfarin: a case-control study. Curr Clin Pharmacol. 2016;11:62-8.Case Control2016-01
Peterson JF et al. Physician response to implementation of genotype-tailored antiplatelet therapy. Clin Pharmacol Ther. 2015 Dec 22 [Epub ahead of print].Retrospective Analysis2015-12
Shi C et al. Pharmacogenetics-based versus conventional dosing of warfarin: a meta-analysis of randomized controlled trials. PLoS One. 2015;10:e0144511.Meta-Analysis2015-12
Trompet S et al. Non-response to (statin) therapy: the importance of distinguishing non-responders from non-adherers in pharmacogenetic studies. Eur J Clin Pharmacol. 2015 Dec 19 [Epub ahead of print].Retrospective Analysis2015-12
Mitchell D et al. Economic evaluation of a pharmacogenomic test for statin-induced myopathy in cardiovascular high-risk patients initiating a statin. Value Health. 2015;18:A396.Cost-Effectiveness Analysis2015-11
Nishimura AA et al. Physician perspectives of CYP2C19 and clopidogrel drug-gene interaction active clinical decision support alerts. Int J Med Inform. 2016;86:117-25.Survey2015-11
Gor D et al. Cost-effectiveness of a novel pharmacist guided warfarin pharmacogenetic service. Value Health. 2015;18:A390.Cost-Effectiveness
Analysis		2015-11
Malhotra N et al. A pharmacodynamic comparison of a personalized strategy for anti-platelet therapy versus ticagrelor in achieving a therapeutic window. Int J Cardiol. 2015;197:318–25.Retrospective Cohort2015-10
Li Y et al. VKORC1 -1639G/A and 1173 C/T genetic polymorphisms influence individual differences in warfarin maintenance dose. Genet Test Mol Biomarkers. 2015;19:488–93.Cohort2015-09
Han Y et al. Influence of genetic polymorphisms on clopidogrel response and clinical outcomes in patients with acute ischemic stroke CYP2C19 genotype on clopidogrel response. CNS Neurosci Ther. 2015;21:692–7.Case-Control2015-09
Saab YB et al. Optimizing clopidogrel dose response: a new clinical algorithm comprising CYP2C19 pharmacogenetics and drug interactions. Ther Clin Risk Manag. 2015;11:1421-7.PK/PD2015-09
Zhang J et al. The influence of VKORC1 gene polymorphism on warfarin maintenance dosage in pediatric patients: A systematic review and meta-analysis. Thromb Res. 2015;136:955-61Meta-Analysis2015-09
Jiang M et al. CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis. Pharmacogenet Genomics. 2015;25:609-17.
Cohort2015-09
Lin M et al. Association between CYP2C19 Polymorphisms and Outcomes in Cerebral Endovascular Therapy. Am J Neuroradiol. 2016;37:108-13Prospective Cohort2015-09
Xu H et al. Comparison of the performance of the warfarin pharmacogenetics algorithms in patients with surgery of heart valve replacement and heart valvuloplasty. Thromb Res. 2015;136:552–9.Retrospective Cohort2015-09
Collet JP et al. Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study. Eur J Clin Pharmacol. 2015;71:1315-24.Randomized Controlled Trial2015-08
Tabib A et al. Enzyme polymorphism in warfarin dose management after pediatric cardiac surgery. Res Cardiovasc Med. 2015;4:e27963.Prospective Cohort2015-08
Shaw K et al. Clinical practice recommendations on genetic testing of CYP2C9 and VKORC1 variants in warfarin therapy. Ther Drug Monit. 2015;37(4):428–36.Systematic Literature Review2015-08
Knauer MJ et al. Clopidogrel and CYP2C19: pharmacogenetic testing ready for clinical prime time? Clin Chem. 2015;61:1235-40. Opinion2015-08
Abohelaika S et al. Influence of CYP2C9 polymorphism on fall in International Normalized Ratio in patients interrupting warfarin therapy before elective surgery. J Thromb Haemost. 2015;13:1436-40.Prospective Cohort2015-08
Wypasek E et al. CYP2C9 polymorphism and unstable anticoagulation with warfarin in patients within the first 3 months following heart valve replacement. Adv Clin Exp Med. 2015;24:607-14.Case-Control2015-08
Pan Y et al. PGWD: Integrating Personal Genome for Warfarin Dosing. Interdiscip Sci. 2016;8:23-7.Description of Web Tool2015-08
Dai DP et al. Identification and characterization of a novel CYP2C9 allelic variant in a warfarin-sensitive patient. Pharmacogenomics. 2015;16:1475-86Description of Novel Variant2015-08
Wei Y-Q et al. Cytochrome P450 CYP 2C19*2 associated with adverse 1-year cardiovascular events in patients with acute coronary syndrome. PLoS ONE. 2015;10(7):e0132561.Prospective Cohort2015-07
You JH. Universal versus genotype-guided use of direct oral anticoagulants in atrial fibrillation patients: a decision analysis. Pharmacogenomics. 2015;16:1089-100Retrospective Cohort2015-07
Tang T et al. Genotype-Guided Dosing of Coumarin Anticoagulants: A Meta-analysis of Randomized Controlled Trials. J Cardiovasc Pharmacol Ther. 2015;20:387–94.Meta-Analysis2015-07
Belley-Cote EP et al. Genotype-guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation. A systematic review and meta-analysis. Thromb Haemost. 2015 Jul 9 [Epub ahead of print]. Meta-Analysis2015-07
Rehman KU et al. Allele frequency distribution of CYP2C19*2 allelic variants associated with clopidogrel resistance in cardiac patients. Exp Ther Med. 2015;10(1):309–15.Cross-Sectional2015-07
Santos PC et al. Development of a pharmacogenetic-based warfarin dosing algorithm and its performance in Brazilian patients: highlighting the importance of population-specific calibration. 2015;16:865-76.Cross Sectional2015-07
Yang Y et al. The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19. Expert Opin Drug Metab Toxicol. 2015 Jul 14 [Epub ahead of print]. Opinion2015-07
Roden DM. Cardiovascular pharmacogenomics: current status and future directions. J Hum Genet. 2015 Jul 16 [Epub ahead of print].Review2015-07
Limdi NA et al. Race influences warfarin dose changes associated with genetic factors. Blood. 2015;126:539-45.
Prospective cohort2015-07
Limdi NA et al. Race influences warfarin dose changes associated with genetic factors. Blood. 2015;126:539-45.Prospective Cohort2015-07
Price ET. Warfarin pharmacogenomics and African ancestry. Blood. 2015;126:434-6.Opinion2015-07
Johnson SG et al. Financial analysis of CYP2C19 genotyping in patients receiving dual antiplatelet therapy following acute coronary syndrome and percutaneous coronary intervention. J Managed Care Spec Pharm. 2015;21:552–7.Cost-effectiveness analysis2015-07
Bryk A et al. Warfarin metabolites in patients following cardiac valve implantation: a contribution of clinical and genetic factors. Cardiovasc Drugs Ther. 2015;29:257-64.Prospective Cohort2015-06
Sleder AT et al. Cardiovascular pharmacokinetics, pharmacodynamics, and pharmacogenomics for the clinical practitioner. J Cardiovasc Pharmacol Ther. 2015 Jun 8 [Epub ahead of print].Perspective2015-06
Kobayashi M et al. A randomized study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of clopidogrel in three different CYP2C19 genotype groups of healthy Japanese subjects. J Atheroscler Thromb. 2015 Jun 9 [Epub ahead of print].PK/PD2015-06
Kaufman AL et al. Evidence for clinical implementation of pharmacogenomics in cardiac drugs. Mayo Clin Proc. 2015;90:716–29.Systematic Review2015-06
Hokimoto S et al. Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy. Thromb Res. 2015;135:1081–6.Prospective Cohort2015-06
Hernandez W et al. Novel single nucleotide polymorphism in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans. Transl Res. 2015;165:651–7.PK / PD2015-06
Ross S et al. Use of genetic data to guide therapy in arterial disease. J Thromb Haemost. 2015;13 Suppl 1:S281–9.Review2015-06
Kimmel SE. Warfarin pharmacogenomics: current best evidence. J Thromb Haemost. 2015;13 Suppl 1:S266–71.Meta-Analysis2015-06
Pereira NL et al. Clinical implementation of cardiovascular pharmacogenomics [Comment]. Mayo Clin Proc. 2015;90:701–4.Comment2015-06
Jiménez-Varo E et al. Extrapolation of acenocoumarol pharmacogenetic algorithms. Vascul Pharmacol. 2015 Jun 27 [Epub ahead of print].Cohort2015-06
Šupe S et al. Clinical application of genotype-guided dosing of warfarin in patients with acute stroke. Arch Med Res. 2015;46:255-73.Prospective Cohort2015-05
Park YK et al. Lack of association of clinical factors (SAMe-TT2R2) with CYP2C9/VKORC1 genotype and anticoagulation control quality. J Stroke. 2015;17:192–8.Prospective Cohort2015-05
Nozari Y et al. The impact of cytochrome P450 2C19 polymorphism on the occurrence of one-year in-stent restenosis in patients who underwent percutaneous coronary intervention: A case-match study. Anatol J Cardiol. 2015;15:348–53.Cross Sectional2015-05
Golukhova EZ et al. Clopidogrel response variability: impact of genetic polymorphism and platelet biomarkers for predicting adverse outcomes poststenting. Am J Ther. 2015;22:222–30.Case Series2015-05
Darbar D. The role of pharmacogenetics in atrial fibrillation therapeutics - Is personalized therapy in sight? J Cardiovasc Pharmacol. 2015 May 9 [Epub ahead of print].Perspective2015-05
Cavallari LH et al. Pharmacogenomics in cardiology - genetics and drug response: 10 years of progress. Future Cardiol. 2015;11:281–6.Commentary2015-05
McDonough CW et al. CYP2C19 metabolizer status and clopidogrel efficacy in the secondary prevention of small subcortical strokes (SPS3) study. J Am Heart Assoc. 2015;4:e001652.Cohort2015-05
Li JH et al. SLCO1B1 genetic variants, long-term low-density lipoprotein cholesterol levels and clinical events in patients following cardiac catheterization. Pharmacogenomics. 2015;16:449–58.Retrospective Cohort2015-04
Yang J et al. CYP2C19 LOF alleles confer no risk for HTPR but higher risk for recurrent ischemic events in clopidogrel treated elderly ACS patients. Int J Cardiol. 2015;189:225–7.Letter 2015-04
Li X et al. Clinical benefits of pharmacogenetic algorithm-based warfarin dosing: meta-analysis of randomized controlled trials. Thromb Res. 2015;135(4):621–9.Meta-Analysis2015-04
Tang HL et al. Limited clinical utility of genotype-guided warfarin initiation dosing algorithms versus standard therapy: a meta-analysis and trial sequential analysis of 11 randomized controlled trials. Pharmacogenomics J. 2015 Apr 14 [Epub ahead of print].Meta-analysis2015-04
So DYF et al. A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study. Pharmacogenomics J. 2015 Apr 7 [Epub ahead of print].Prospective, randomized2015-04
Shahabi P et al. Cardiovascular pharmacogenomics; state of current knowledge and implementation in practice. Int J Cardiol. 2015;184:772795.Review2015-04
Oikonomou E et al. Genetic testing and antiplatelet treatment: Still way to go? Int J Cardiol. 2015;187:63–5.Editorial2015-04
Niu X et al. CYP2C19 polymorphism and clinical outcomes among patients of different races treated with clopidogrel: a systematic review and meta-analysis. J Huazhong Univ Sci Technolog Med Sci. 2015;35:147–56.Meta-analysis2015-04
Hokimoto S et al. Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in choronary heart disease patients during dual antiplatelet therapy. Thromb Res. 2015;135:1081-6.Prospective Cohort2015-04
Samardzic J et al. CYP2C19*2 genotype influence in acute coronary syndrome patients undergoing serial clopidogrel dose tailoring based on platelet function testing: Analysis from randomized controlled trial NCT02096419. Int J Cardiol. 2015;186:282–5.Post-hoc analysis2015-03
Abohelaika S et al. The impact of genetics on the management of patients on warfarin awaiting surgery. Age Ageing. 2015 Mar 10 [Epub ahead of print].Case Report2015-03
Mega JL et al. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015 Mar 10 [Epub ahead of print].Sub-Group Analysis 2015-03
Marume K et al. Intraprocedural thrombotic event during coronary intervention depends on CYP2C19 genotype and is a predictor of future clinical event. Int J Cardiol. 2015;187:231–33.Descriptive report2015-03
Li S et al. Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus assessed by follow-up optical coherence tomography in Chinese patients receiving clopidogrel. J Thromb Thrombolysis. 2015;40:88-96.Retrospective cohort2015-03
Lee JA et al. Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients. Pharmacogenomics. 2015;16:303–13.Retrospective Cohort2015-03
Barajas MR et al. A patient-centered approach to the development and pilot of a warfarin pharmacogenomics patient education tool for health professionals. Curr Pharm Teach Learn. 2015;7:249–55.Pilot2015-03
Nagai R et al. Factors influencing pharmacokinetics of warfarin in African-Americans: implications for pharmacogenetic dosing algorithms. Pharmacogenomics. 2015;16:217–25.Lync PK2015-03
Li X et al. Clinical benefits of pharmacogenetic algorithm-based warfarin dosing: meta-analysis of randomized controlled trials. Thromb Resh. 2015 Jan 17 [Epub ahead of print].Meta-analysis2015-01
Tang N et al. The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese patients. Scand J Clin Lab Invest. 2015a;1–7.Prospective cohort2015-01
Tang T et al. Genotype-guided dosing of coumarin anticoagulants: a meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther. 2015 Jan 8 [Epub ahead of print].Meta-analysis2015-01
Baranova EV et al. Genotype-guided coumarin dosing: where are we now and where do we need to go next? Expert Opin Drug Metab Toxicol. 2015;1–14.Review2015-01
Verhoef TI et al. Economic evaluation of a pharmacogenetic dosing algorithm for coumarin anticoagulants in the Netherlands. Pharmacogenomics. 2015;16:101–114.Cost-effective analysis2015-01
Birmingham BK et al. Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States. Eur J Clin Pharmacol. 2015 Jan 30 [Epub ahead of print].PK2015-01
Mitropoulou C et al. Economic evaluation of pharmacogenomic-guided warfarin treatment for elderly Croatian atrial fibrillation patients with ischemic stroke. Pharmacogenomics. 2015;16:137–48.Cost-effective analysis2015-01
Carnes CA. What is the role of pharmacogenetics in optimization of warfarin dosing? Trends Cardiovasc Med. 2015;25:42–3.Editorial Commentary2015-01
Johnson JA et al. Warfarin pharmacogenetics. Trends Cardiovasc Med. 2015;25:33–41.Review2015-01
Bousoula E et al. Pharmacogenetics and statin treatment: reality or theory? Curr Vasc Pharmacol. 2015 Jan 30 [Epub ahead of print].Review2015-01
Chong HY et al. Cost-effectiveness analysis of pharmacogenetic-guided warfarin dosing in Thailand. Thromb Res. 2014;134:1278–84.Cost-effectiveness analysis2014-12
Drozda K et al. Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans. Pharmacogenet Genomics. 2014 Dec 1 [Epub ahead of print].Cohort2014-12Warfarin: Including genotypes important for African Americans leads to better dose prediction
Wang X-Q et al. Genetic polymorphisms of CYP2C19*2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome. Gene. 2014a Dec 24 [Epub ahead of print].PK2014-12
Zhang L et al. Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis. Thromb Res. 2014 Dec 9 [Epub ahead of print].Meta-analysis2014-12
Wang Z-Q et al. Pharmacogenetics-based warfarin dosing algorithm decreases time to stable anticoagulation and the risk of major haemorrage: an updated meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol. 2014 Dec 30 [Epub ahead of print].Meta-analysis2014-12
Qiu L-N et al. Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel. Eur J Pharmacol. 2014;747C:29–35.Prospective Cohort2014-12
Kawai VK et al. Genotype and risk of major bleeding during warfarin treatment. Pharmacogenomics. 2014;15:1973–83.Retrospective Cohort2014-12
Hawcutt DB et al. Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects. Pharmacogenomics J. 2014;14:542–8.Cohort2014-12
Hopewell JC et al. Pharmacogenomics of statin therapy: any new insights in efficacy or safety? Curr Opin Lipidol. 2014 Dec 25 [Epub ahead of print].Review2014-12
Xu H et al. Meta-analysis of efficacy and safety of genotype-guided pharmacogenetic dosing of warfarin. Int J Cardiol. 2014;177:654–7.Meta-analysis2014-12
Ismail S et al. Genotype- and phenotype-directed antiplatelet therapy selection in patients with acute coronary syndromes. Expert Rev Cardiovasc Ther. 2014;12:1289–1303.Review2014-11
Konishi A et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism on intra-stent thrombi and lesion outcome after everolimus-eluting stent implantation compared to that after first-generation drug-eluting stent implantation. Int J Cardiol. 2014 Nov 6 [Epub ahead of print].Prospective Cohort2014-11
Parikh KS et al. Potential applications of pharmacogenomics to heart failure therapies. Heart Fail Clin. 2014;10:599–606.Review2014-11
Iwuchukwu OF et al. Genetic variation in the UGT1A locus is associated with simvastatin efficacy in a clinical practice setting. Pharmacogenomics. 2014;15:1739–47.Retrospective cohort2014-11
Fontana V et al. Large-scale gene-centric analysis identifies polymorphisms for resistant hypertension. J Am Heart Assoc. 2014;3:e001398. 

Cross-sectional		2014-11
Meyer Zu Schwabedissen HE et al. Function-impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacy of statins in a population-based cohort. Pharmacogenet Genomics. 2014 Jan 25 [Epub ahead of print].Post-hoc analysis2014-11
Martínez-Quintana E et al. Clopidogrel: A multifaceted affair. J Clin Pharmacol. 2014; [Epub ahead of print 2014 Oct 18].Opinion2014-10
Lindgren A. Stroke genetics: a review and update. J Stroke. 2014;16:114–23.Review2014-10
Wadelius M. Warfarin pharmacogenetics: it matters if you’re black or white. Blood. 2014;124:2171.Commentary2014-10
Guo B et al. Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease. J Vasc Surg. 2014;60:993–1001.Prospective Cohort Study2014-10
Postmus I et al. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat Commun. 2014;5:5068.Meta-Analysis2014-10
Miura G et al. Genetic and non-genetic factors responsible for antiplatelet effects of clopidogrel in Japanese patients undergoing coronary stent implantation: An algorithm to predict on-clopidogrel platelet reactivity. Thromb Res. 2014;134:877–83.Prospective Observational Study2014-10
Suarez-Kurtz G et al. Pharmacogenetics of coumarin anticoagulants in Brazilians.  Expert Opin Drug Metab Toxicol. 2014 Oct 25 [Epub ahead of print].Opinion2014-10
De Oliveira Almeida VC et al. Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 Genes and the Therapeutic Warfarin Dose in Brazilian Patients with Thrombosis: A Prospective Cohort Study. Mol Diagn Ther. 2014 Oct 14 [Epub ahead of print].Prospective cohort study2014-10
Kishan SP et al. Potential Applications of Pharmacogenomics to Heart Failure Therapies, Heart Fail Clin. 2014;10:599–606.Review

 		2014-10
Jiménez-Varo E et al. Prediction of stable acenocoumarol dose by a pharmacogenetic algorithm. Pharmacogenet Genomics. 2014;24:501–13.Retrospective Observational Study2014-10
Tresukosol D et al. Effects of Cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease. PLoS ONE. 2014;9:e110188.Prospective cohort2014-10
Oni-Orisan A et al. Pharmacogenomics in heart failure: where are we now and how can we reach clinical application? Cardiol Rev. 2014;22:193-8.Review2014-09 
Franchini M et al. Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis. J Thromb Haemost. 2014;12:1480-7.Meta-Analysis2014-09New meta-analysis shows 50 percent decrease in serious bleeding with genotype-guided warfarin
Gurbel PA et al. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease. 2014;112:589-97.PK/PD2014-09 
Sorich MJ et al. CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following PCI and in Asian Populations treated with clopidogrel: a meta-analysis. Circ Cardiovasc Genet. 2014 Sep 25 [Epub ahead of print].Meta-Analysis2014-09 
Hou X et al. Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis. Eur J Clin Pharmacol. 2014;70:1041-7.Meta-Analysis2014-09 
Li X et al. Effect of CYP2C9-VKORC1 interaction on warfarin stable dosage and its predictive algorithm. J Clin Pharmacol. 2014 Sep [Epub ahead of print].Descriptive2014-09 
Marbach JA et al. Novel treatments for familial hypercholesterolemia: pharmacogenetics at work. Pharmacotherapy. 2014;34:961-72.Review2014-09 
Karnik N et al. CYP2C9FN*3 polymorphism presenting as lethal subdural hematoma with low-dose warfarin. Indian Journal of Pharmacology. 2014;46:549.Case report2014-09 
Siller-Matula JM et al. How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors- is an algorithm the answer? Thrombosis and Haemostasis. 2014;112(6).Systematic review2014-09 
Jimenes-Varo E et al. Pharmacogenetics role in the safety of acenocoumarol therapy. Thromb Haemost. 2014;112:522-36.Cohort2014-09 
Gaikwad T et al. VKORC1 and CYP2C9 genotype distribution in Asian countries. Thromb Res. 2014;134:537-44.Descriptive2014-09 
Sun W et al. Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel. Platelets. 2014 Sep 10;1–5 [Epub ahead of print].Prospective cohort2014-09 
Valentin II et al. Pharmacogenetic association study of warfarin safety endpoints in Puerto Ricans. P R Health Sci J. 2014;33:97-104.Retrospective cohort2014-09 
Fontana V et al. An update on the pharmacogenetics of treating hypertension. J Hum Hypertens. 2014 Aug 28 [Epub ahead of print].Review2014-08
Kirchhof P et al. The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology. Eur Heart J. 2014 Aug; [Epub ahead of print].Review

 		2014-08New Position Statements Give Guidance on Personalized Medicine In Cardiology, Oncology
Brunner-Ziegler S et al. Influence of proton pump inhibitors and VKORC1 mutations on CYP2C9-mediated dose requirements of vitamin K antagonist therapy: a pilot study. Br J Haematol. 2014 Aug; [Epub ahead of print].Retrospective cohort study

 		2014-08 
Arima Y et al. Comparison of the effect of CYP2C19 polymorphism on clinical outcome between acute coronary syndrome and stable angina. J Cardiol. 2014 Aug; [Epub ahead of print].Prospective cohort study

 		2014-08 
Zhuang W et al. Effect of CYP2C9, CYP4F2 and VKORC1 genetic polymorphisms on pharmacokinetics and pharmacodynamics of mean daily maintenance dose of warfarin in Chinese patients. Blood Coagul Fibrinolysis. 2014 Oct 10 [Epub ahead of print].PK/PD Study2014-08
Kim HS. The effect of CYP2C19 genotype on the time course of platelet aggregation inhibition after clopidogrel administration. J Clin Pharmacol. 2014;54:850–7.Prospective cohort study

 		2014-08 
Horenstein RB et al. Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers. J Clin Pharmacol. 2014;54:865–73.Prospective cohort study

 		2014-08Clopidogrel in CYP2C19 Poor Metabolizers: Four-Fold Dose Increase Needed
Hariharan S et al. Clopidogrel, CYP2C19 and proton pump inhibitors: What we know and what it means. J Clin Pharmacol. 2014;54:884-8. Commentary2014-08 
Koller EA et al. Genotype-guided dosing of vitamin K antagonists. N Engl J Med. 2014;370:1761-66.Correspondence2014-08 
Langaee T et al. The influence of the CYP2C19*10 allele on clopidogrel activation and CYP2C19*2 genotyping. Pharmacogenet Genomics. 2014;24:381-6. Genotype analysis2014-08 
Liu T et al. CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention. Coronary Artery Disease.2014 [Epub ahead of print]. Prospective cohort2014-08 
Baranova EV et al. The COAG and EU-PACT Trials: What is the Clinical Benefit of Pharmacogenetic-Guided Coumarin Dosing During
Therapy Initiation? Curr Mol Med. 2014 Aug; [Epub ahead of print].		Review

 		2014-08 
Tang Q et al. Outcomes of pharmacogenetics-guided dosing of warfarin: A systematic review and meta-analysis. Int J Cardiol. 2014;175:587–91.Meta-Analysis

 		2014-08 
Stitham J et al. Cardiovascular Pharmacogenetics of Anti-Thrombotic Agents and Non-Steroidal Anti-Inflammatory Drugs. Curr Mol Med.
2014 Aug; [Epub ahead of print].		Review

 		2014-08 
Kazi DS et al. Warfarin, genes, and the (health care) environment. JAMA Intern Med. 2014;174:1338-9.Commentary2014-08Meta-analysis of genotype-guided warfarin trials yields disappointing results
Stergiopoulos K et al. Genotype-guided vs clinical dosing of warfarin and Its analogues: meta-analysis of randomized clinical trials. JAMA Intern Med. 2014;174:1330-8.Meta-Analysis2014-08Meta-analysis of genotype-guided warfarin trials yields disappointing results
Karazniewicz-Lada M, et al. The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. J Clin Pharmacol. 2014;54:874-80.Cross-sectional2014-08 
Munshia A et al. Genetic signatures in the treatment of stroke. Current Pharmaceutical Design. 2014 Aug 26; [Epub ahead of print].Review2014-08 
Horenstein RB et al. Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers. J Clin Pharmacol. 2014;54:865-73. Crossover study2014-08 Clopidogrel in CYP2C19 poor metabolizers: Four-fold dose increase may be needed
Franchini M et al. Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis. J Thromb Haemost. 2014; [Epub ahead of print]. Meta-Analysis2014-07 
Stimpfle F et al. Impact of point-of-care testing for CYP2C19 on platelet inhibition in patients with acute coronary syndrome and early dual antiplatelet therapy in the emergency setting. Thromb Res. 2014 May 10. [Epub ahead of print].Retrospective cohort study2014-07 
Sardella G et al. The importance of genotype variation beyond different antiplatelet therapy in nonresponder patients. J Am Coll Cardiol. 2014;64:333-4. Letter2014-07 
Cavallari LH et al. Warfarin pharmacogenetics: to genotype or not to genotype, that is the question. Clin Pharmacol Ther. 2014;96:22-4. Commentary2014-07 
Hawcutt D et al. Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects. Pharmacogenomics J. 2014. [Epub ahead of print].Cross-sectional analysis2014-07 
Depta J et al. Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction. Pharmacogenomics J. 2014; [Epub ahead of print]. Retrospective analysis2014-07 
Bergmeijer TO et al. CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients: rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study. Am Heart J. 2014;168:16–22. Descriptive2014-07 
Mizobe M, et al. Impact of CYP2C19 polymorphism on clinical outcome following coronary stenting is more important in non-diabetic than diabetic patients. Thromb Res. 2014 Apr 26; [Epub ahead of print]. Prospective cohort study2014-07 
Gryn SE et al. Pharmacogenomics, lipid disorders, and treatment options. Clin Pharmacol Ther. 2014;96:36-47. Review2014-07 
Hata M et al. Incidence of Drug Interaction When Using Proton Pump Inhibitor and Warfarin According to Cytochrome P450 CYP2C19 (CYPCYP2C19) Genotype in Japanese. Thorac Cardiovasc Surg. 2014 Jul; [Epub ahead of print].Prospective cohort2014-07 
Cavallari LH et al. Warfarin pharmacogenetics: to genotype or not to genotype, that is the question. Clin Pharmacol Ther. 2014;96:22–4.Review

 		2014-07 
Ramsey L et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update. Clin Pharmacol Ther. 2014; [Epub ahead of print]. 

 		Guideline2014-07Updated SLCO1B1–simvastatin guideline provides resources to support clinical implementation
Hou X et al. Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis. Eur J Clin Pharmacol. 2014;70:1041-7.Meta-Analysis2014-07 
Goulding R et al. Genotype-guided Drug Prescribing: A Systematic Review and Meta-analysis of Randomized Control Trials. Br J Clin Pharmacol. 2014; [Epub ahead of print]. Meta-Analysis2014-07 
Maitland-van der Zee AH, et al. Patients benefit from genetics-guided coumarin anticoagulant therapy. Clin Pharmacol Ther.2014; 96:15-7.  Commentary2014-07 
Lachance K et al. Opinions, hopes and concerns regarding pharmacogenomics: a comparison of healthy individuals, heart failure patients and heart transplant recipients. Pharmacogenomics J. 2014; [Epub ahead of print].Survey2014-07 
Patel V et al. Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention. Pharmacy Practice. 2014a;12:438.Cost-utility analysis2014-07 
Baker WL et al. New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics? Clin Pharmacol Ther. 2014;96:17-9. Perspective2014-07 
Osnabrugge RL et al. A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users.Genet Med. 2014 Jun 9; [Epub ahead of print]. Systematic review2014-06 
Hokimoto S, et al. Impact of CYP3A5 polymorphism on platelet reactivity at percutaneous coronary intervention and after 9 months of aspirin and clopidogrel therapy in Japanese patients with coronary artery disease. Eur J Clin Pharmacol. 2014;70:667-73.  Prospective cohort study2014-06 
Cresci S et al. Cytochrome P450 Gene Variants, Race, and Mortality Among Clopidogrel Treated Patients Following Acute Myocardial Infarction. Circ Genetics. 2014;7:277-86.Prospective cohort study2014-06Clopidogrel: CYP2C19, CYP1A2 effects in some post-MI patients
An Sh et al. Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves. J Clin Pharm Ther. 2014; [Epub ahead of print]. Cross-sectional2014-06 
Vear SI et al. The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population. Br J Haematol. 2014 [Epub ahead of print]. Cross-sectional2014-06 
Koller EA, et al. Genotype-guided dosing of vitamin K antagonists. N Engl J Med. 2014;370:1761-66. Correspondence2014-05 
Guo B et al. Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease. J Vasc Surg. 2014; [Epub ahead of print]. Retrospective cohort study2014-05 
Daly PL et al. Pharmacogenetics of antiplatelet therapy. Curr Atheroscler Rep. 2014;16:411. Review2014-05 
Talameh JA et al. Pharmacogenetics of Statin-Induced Myopathy: A Focused Review of the  Clinical Translation of Pharmacokinetic Genetic Variants. J Pharmacogenomics Pharmacoproteomics. 2014;5:128. Review2014-04 
Scott SA et al. Warfarin pharmacogenetic trials: is there a future for pharmacogenetic-guided dosing? Pharmacogenomics. 2014;15:719-22.  Editorial2014-04 
Kazi DS et al. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. Ann Intern Med. 2014;160:221–32.Cost-Effective Analysis2014-02

Tagged as: , ,